---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-017392"
form_type: "8-K"
ticker: "CMPS"
cik: "0001816590"
company_name: "COMPASS Pathways plc"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:36:54.505960+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# COMPASS Pathways Q1 net loss $24.2M ($0.57/sh); Phase 3 psilocybin trials underway

## Summary
- Net loss $24.2M ($0.57 loss per share) vs $21.2M ($0.50) in Q1 2022.
- Cash $117.1M at March 31, 2023; raised additional $26.9M net via ATM in Q2.
- Phase 3 pivotal trials (COMP 005, COMP 006) in TRD underway; top-line data expected summer 2024 and mid-2025.
- CPT III code for psychedelic therapy support accepted by AMA, effective Jan 1, 2024.
- FY 2023 net cash used in operating activities guidance $85M-$110M; Q2 guidance $22M-$30M.

## SEC filing metadata
- accession: 0001628280-23-017392
- form_type: 8-K
- ticker: CMPS
- cik: 0001816590
- company_name: COMPASS Pathways plc
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/0001628280-23-017392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/cmps-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-017392
- JSON: https://secwatch.observer/filing/0001628280-23-017392.json
- Plain text: https://secwatch.observer/filing/0001628280-23-017392.txt

## Key facts
- Earnings Releases
  COMPASS Pathways plc reported the three months ended March 31, 2023 results: net income $24.2 million, EPS $0.57 loss per share.
  - Period: the three months ended March 31, 2023
  - Net income: $24.2 million
  - EPS: $0.57 loss per share
  - Result: reported results
  source text: Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/0001628280-23-017392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.